Acute Myelogenous Leukemia

Genetics, Biology and Therapy

  • Lalitha Nagarajan

Part of the Cancer Treatment and Research book series (CTAR, volume 145)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Zeev Estrov
    Pages 1-17
  3. Yasuhiro Oki, Jean - Pierre J. Issa
    Pages 19-40
  4. Lalitha Nagarajan
    Pages 59-66
  5. Derek L. Stirewalt, Soheil Meshinchi
    Pages 85-108
  6. Beatrice U. Mueller, Thomas Pabst
    Pages 109-125
  7. Michael E. Engel, Scott W. Hiebert
    Pages 127-147
  8. Milena S. Nicoloso, Bharti Jasra, George A. Calin
    Pages 169-181
  9. Julie M. Fortier, Timothy A. Graubert
    Pages 183-196
  10. Ismael Samudio, Marina Konopleva, Bing Carter, Michael Andreeff
    Pages 197-217
  11. David Grimwade, Anita R. Mistry, Ellen Solomon, Fabien Guidez
    Pages 219-235
  12. Gheath Alatrash, Jeffrey J. Molldrem
    Pages 237-255
  13. Gautam Borthakur, Elihu E. Estey
    Pages 257-271
  14. Back Matter
    Pages 273-280

About this book

Introduction

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages.

Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

 

"The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise."

Steven T. Rosen, M.D.
Series Editor

Keywords

apoptosis cell classification genetics immunotherapy leukemia pathogenesis stem cell targeted therapy

Editors and affiliations

  • Lalitha Nagarajan
    • 1
  1. 1.Dept. of GeneticsMD Anderson Cancer CenterHoustonUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-0-387-69259-3
  • Copyright Information Springer-Verlag New York 2010
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-0-387-69257-9
  • Online ISBN 978-0-387-69259-3
  • Series Print ISSN 0927-3042
  • About this book